Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2026
Perioperative Ketamine and Esketamine for Enhanced Recovery After Surgery (ERAS): A Systematic Review.
Систематический обзорСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Muhan, Zhu Rongjie, She Yong-Jun, Sun Yuyu, Xu Li, Rosenquist Richard, Yao Ming, Han Xudong, Xu Jijun
Аннотация
BACKGROUND: Enhanced recovery after surgery (ERAS) protocol optimizes perioperative care and accelerates recovery. Ketamine and esketamine are increasingly incorporated into ERAS strategies.
OBJECTIVES: This systematic review critically examines the evidence of perioperative ketamine and esketamine use within ERAS, focusing on postoperative pain, opioid consumption, nausea and vomiting, cognitive function, depression, and sleep quality.
METHODS: Randomized controlled trials, meta-analyses, systematic reviews, and relevant clinical guidelines were identified. Evidence for each outcome was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
RESULTS: Perioperative ketamine or esketamine consistently reduces postoperative pain and opioid consumption, particularly within the first 24-48 h after surgery. Both agents were associated with reductions in early postoperative depressive symptoms, especially among patients with preexisting depression. Evidence regarding postoperative neurocognitive disorders, including delirium and cognitive dysfunction, remains insufficient. Moderate-certainty evidence supports esketamine-associated improvements in postoperative nausea and vomiting and early postoperative sleep quality, particularly within 72 h after surgery.
DISCUSSION: Perioperative ketamine and esketamine are valuable adjuncts to ERAS multimodal analgesia, with evidence also supporting their effects on depressive and sleep disorders. However, evidence is limited by high heterogeneity, small sample sizes, underpower, inconsistent or non-standardized outcome assessment tools, and short follow-up durations. Optimal dosing strategies remain undetermined.
OBJECTIVES: This systematic review critically examines the evidence of perioperative ketamine and esketamine use within ERAS, focusing on postoperative pain, opioid consumption, nausea and vomiting, cognitive function, depression, and sleep quality.
METHODS: Randomized controlled trials, meta-analyses, systematic reviews, and relevant clinical guidelines were identified. Evidence for each outcome was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.
RESULTS: Perioperative ketamine or esketamine consistently reduces postoperative pain and opioid consumption, particularly within the first 24-48 h after surgery. Both agents were associated with reductions in early postoperative depressive symptoms, especially among patients with preexisting depression. Evidence regarding postoperative neurocognitive disorders, including delirium and cognitive dysfunction, remains insufficient. Moderate-certainty evidence supports esketamine-associated improvements in postoperative nausea and vomiting and early postoperative sleep quality, particularly within 72 h after surgery.
DISCUSSION: Perioperative ketamine and esketamine are valuable adjuncts to ERAS multimodal analgesia, with evidence also supporting their effects on depressive and sleep disorders. However, evidence is limited by high heterogeneity, small sample sizes, underpower, inconsistent or non-standardized outcome assessment tools, and short follow-up durations. Optimal dosing strategies remain undetermined.